Erik van den Berg
Erik has over seventeen years experience in the pharmaceutical and biotechnology industries. He joined AM-Pharma in September 2007 as Chief Business Officer and became the company's CEO in 2011.
Previously, as a Senior Executive at Organon (NL) he was responsible for leading the Company’s global biotechnology business development. At Organon, he also held European Business Development as well as Marketing and Sales roles relating to the Company’s biotechnology services.
Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships and raised more than €130M in equity and debt financing for biotechnology companies. He is also the founder and board member of two high-tech start-up companies.
Erik has a MSc in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK).
Academic research institutes are cradles of knowledge and inventions, sometimes resulting in successful products that are commercialized by industry. Collaborations between academia and industry are not always easy. There may be a different appreciation of the length and risk of the development process needed to transform an invention into a successful product. This may result in different expectations as to the value of the invention. These opposing perspectives may complicate a fruitful collaboration. But what formats can lead to mutual benefit? Do both partners need each other? Is it important to patent the invention, and what rules for ownership may apply? In this track, representatives from both sides will give their opinion on requirements for a successful collaboration.